Posters

Assessment of corneal biomechanical properties in glaucomatous patients by ocular response analyzer

Poster Details

First Author: W.Ghobashy EGYPT

Co Author(s):    M. Shahin   A. Gaballa   M. Ammar              

Abstract Details

Purpose:

To describe corneal biomechanics profile in glaucoma patients, and to compare between corneal biomechanics of normal individuals and glaucoma patients.

Setting:

Ophthalmology Department, Suez Canal University Hospital, Ismailia, Egypt.

Methods:

The study included Group A: of 41 eyes receiving medical treatment for glaucoma (diagnosed by elevated IOP, gonioscopy, decreased RNFL by Stratus OCT and searched for visual field Loss using Humphery field analyzer, Carl Zeiss Meditec, Germany). Group B: of 41 normal eyes of individuals with matching age and sex. Subjects with previous ocular surgeries, or any coexisting ocular diseases such as corneal pathology were excluded. Examination included UCVA, BCVA, refraction, slit lamp biomicroscopy and dilated fundus examination. Corneal biomechanics parameters: CH, CRF, IOPg, IOPcc as well as CCT were measured using Ocular Response Analyzer by Reichert, NY.

Results:

The mean age of group A was 49.7 yrs. ± 14.8 and 46 yrs. ± 13.7 in group B, with males constituted 56.5% of group A and 44.4% of group B. Although there was no significant difference between CCT in both groups, Corneal hysteresis was significantly lower in glaucomatous eyes with a mean of 7.7±1.3 in comparison to 9.4± 1.5 in normal eyes.(p=0.001). Conversely, corneal resistance factor was found to be significantly higher in group A with a mean of 11.2± 2.3 compared to 9.7± 1.5 in group B (p=0.001). The IOPcc was found to be significantly higher than IOPg in both groups and this was remarkable in glaucomatous eyes.

Conclusions:

Glaucomatous eyes tend to have lower values of corneal hysteresis and higher values of corneal resistance factor when compared to normal eyes. This seems to be independent from the central corneal thickness. IOPcc measurement should be considered in evaluation and follow up of glaucomatous eyes.

Financial Disclosure:

NONE